Authors
Latest:
Dr. Ferris on the Safety Profile of Transoral Robotic Surgical Resection in Oropharynx CancerRobert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.
Latest:
Dr. Fine on GTX in Inoperable Pancreatic CancerRobert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma
Latest:
Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast CancerRobert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.
Latest:
Dr. Redner on the Activity of Venetoclax in AMLRobert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses the activity of venetoclax (Venclexta) in acute myeloid leukemia (AML).
Latest:
Dr. Talley on Clinical Trials for Patients With Chronic LeukemiasRobert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.
Latest:
Robert Laszewski on the Effect of ACA on Urology PracticesRobert Laszewski, President, Health Policy and Strategy Associates, LLC, discusses the effects of the Affordable Care Act (ACA) on urology practices.
Latest:
Dr. Ferris on Combining STING Agonists With Checkpoint Inhibitors in Head and Neck CancerRobert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.
Latest:
Dr. Jotte on the Low Rate of Screening in Lung CancerRobert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.
Latest:
Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R MyelomaRobert M. Rifkin, MD, FACP, discusses the use of prophylactic tocilizumab to reduce teclistamab-related CRS in relapsed/refractory myeloma.
Latest:
Dr. Wenham on the Importance of Clinical Trials in Ovarian CancerRobert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.
Latest:
Robert McCormack Explains the CellSearch CTC TestRobert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.
Latest:
Dr. Montal on Molecular Predictors of Recurrence With Adjuvant Sorafenib in HCCRobert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
Latest:
Dr. Pirker on New Clinical Trial Designs in Lung CancerRobert Pirker, MD, Department of Medicine I, Medical University of Vienna, discusses novel clinical trial designs that researchers should use going forward in lung cancer.
Latest:
Dr. Kuske on APBI Via Multicatheter Interstitial BrachytherapyRobert R. Kuske, MD, radiation oncologist, Arizona Breast Cancer Specialists, discusses the analysis of the Pooled Registry of Multicatheter Interstitial Sites Experience, which examined the safety of accelerated partial breast irradiation via multicatheter interstitial brachytherapy.
Latest:
Loving Lemons Even When You Wanted OrangesRobert Ramirez, DO, FACP, details his path to clinical thoracic oncology after originally planning on entering the academic field early in his career.
Latest:
Navigating the EHR Marketplace How to Choose the Right EHR for Your Oncology PracticeNavigating the EHR marketplace can be dizzying, with numerous products available to choose from, including locally installed client/server systems that require server hardware, local networks, data backup, and IT support, as well as hosted, Web-based systems.
Latest:
Unmet Needs in the Management of Advanced RCCDrs Alter and Diamond muse about the unmet needs in advanced RCC treatment.
Latest:
Dr. Siegel on Induction Therapy for Head and Neck CancerRobert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses induction therapy for head and neck cancer.
Latest:
New Methods of Boosting Response to Bladder Cancer Immunotherapy ExploredAlthough bacillus Calmette-Guérin (BCG) therapy has significantly improved outcomes for patients with non–muscle invasive bladder cancer since its introduction nearly 40 years ago, there is a pressing need to enhance responses to BCG and to distinguish which patients would respond to treatment early on in the course of therapy.
Latest:
City Oncologist or Country Oncologist?There are multiple factors to consider when deciding whether to practice in an country or a city setting
Latest:
Models Pave the Way for Improved Outcomes in MedulloblastomaTo discover targeted therapies for the more common and severe types of medulloblastoma, a laboratory at Sanford Burnham Prebys Medical Discovery Institute has led efforts to develop genetically engineered mouse models and patient-derived xenografts for studying the molecular basis of the disease.
